Company / Cash per Share
CytomX Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.09
FY2025
5-year range
$0.09 / $3.14
FY2021-FY2025
Trend
-80.7%
vs FY2024
Sector context
#201 of 205
Health Care
What the data says
Among 205 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 2% for cash per share. Cash per Share has fluctuated over the past 10 years, ranging from $0.09 in FY2025 to $5.49 in FY2018.
Based on SEC 10-K filings.
0.09 in FY2025 with a 5-year CAGR of -53.5%.
Declined from $0.26 to $0.09 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -68.4%
- 5-Year CAGR
- -53.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 205This company $0.09 Sector average $72.93
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2025, cash per share decreased 80.7% year-over-year.
- Ranks #201 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.09 | -80.7% |
| FY2024 | $0.48 | +86.2% |
| FY2023 | $0.26 | -91.3% |
| FY2022 | $2.92 | -7.0% |
| FY2021 | $3.14 | -25.4% |
| FY2020 | $4.21 | +1.8% |
| FY2019 | $4.14 | -24.6% |
| FY2018 | $5.49 | +19.0% |
| FY2017 | $4.61 | +60.9% |
| FY2016 | $2.87 | -67.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026